Novartis Q3 Performance
Novartis' Q3 performance was driven by fast growth in recently label-expanded drugs, despite facing generic competition. Net sales rose 7% in constant currencies to $13.9bn, in line with Wall Street forecasts.
Core operating income reached $5.46bn, slightly above consensus analyst predictions of $5.4bn. The company's oncology segment was a key driver of growth, with breast cancer treatment Kisqali (ribociclib) growing by 68% in Q3 2025 compared to Q3 2024.
The gold standard of business intelligence.
Novartis' Q3 update comes amid a deal-making spree to counter generic headwinds. The company is focusing on recently expanded drugs to fuel growth.
Author's summary: Novartis reports 7% sales growth.